You are required to be logged in to access the full website
Click here if you have forgotten your username or password
Therapy Areas
9 September 2026 - Biotechnology company Tyra Biosciences Inc (Nasdaq: TYRA) reported on Wednesday that its initial Phase 2 SURF302 results for oral dabogratinib in patients with FGFR3-altered low-grade intermediate-risk non-muscle invasive bladder c...
9 September 2026 - Biopharmaceutical company Harbour BioMed (HKEX: 02142) reported on Wednesday that its partner company Solstice Oncology has launched with a USD225m Series A financing led by RA Capital Management, with participation from Canaan Par...
9 September 2026 - Oncology-focused biotechnology company Kazia Therapeutics Limited (NASDAQ: KZIA) declared on Monday that the first patient has been dosed in the Arm A of PNOC035, a Phase 2 platform study evaluating paxalisib plus gemcitabine in pa...
9 September 2026 - Life sciences and diagnostics company Revvity Inc (NYSE:RVTY) announced on Wednesday that it has agreed to acquire France-based biotechnology company Human Cell Design (HCD), strengthening its portfolio of human-relevant cell model...
9 September 2026 - Clinical-stage biotechnology company Lakewood-Amedex Biotherapeutics Inc (NASDAQ:LABT) announced on Tuesday that its CEO, Kelvin Cooper, Ph.D., will deliver a virtual presentation at the H.C. Wainwright 28th Annual Global Investmen...
9 September 2026 - Altesa BioSciences, a clinical-stage pharmaceutical company focused on chronic lung diseases including COPD and asthma, announced on Tuesday new clinical data showing that its investigational antiviral therapy, vapendavir, signific...
7 September 2026 - Biopharmaceutical company AstraZeneca PLC (STO: AZN; LON: AZN; NYSE: AZN) said on Monday that US regulators have granted accelerated approval for Etcamah (camizestrant), its next-generation oral selective oestrogen receptor degrade...